R&D efficiency has been in decline for many years, but now with bodies, like the FDA, aiming to accelerate approval times and a critical need for new therapies to combat antibiotic resistant strains of bacteria will we see the tide turn?
A recently published report, sponsored by Novartis, has described the potential benefits of the NHS only paying for drugs that actually work as a new model to address affordability and reduce risks within the health system.
According to research recently performed by SEA Vision and Zenith Technologies, 40% of pharmaceutical industry professionals are lacking confidence in their ability to meet the upcoming US and European serialisation deadlines.
The fourth CPhI Korea is set to take place in August in Seoul, where the event organisers have revealed that there will be a 13% rise in the number of exhibitors and double the amount of overseas buyers since 2015.
In this instalment to our human interest series, we speak to the new business development executive to the North American clinical sales team of PCI Clinical Services, Jamie Weishaar.
In our inaugural Q&A of our new ‘Meet the maker’ series, EPM gets to know Ashley Parish, who has recently been appointed vice president, strategic alliances of teckro — a global life sciences mobile technology company
With patient adherence and prevention of overdose hot topics for pharma, regulatory and healthcare sectors, the rise of implants for the sustained and controlled delivery of drugs is perhaps an inevitable trend.
As Catalent further expands its softgel drug delivery capabilities with its acquisition of Accucaps, we speak with June Lin, global marketing director consumer health softgel, about the benefits these expanded capabilities will offer.
Helping people to help themselves, Daniel Simmons, principal human factors consultant, CCD, reveals the role of human factors in medical adherence and how patients use their senses and make sense of things.
